Tag Archive for: Loqtorzi

Junshi Biosciences and Coherus BioSciences unveiled data from the Phase III HEPATORCH study, showing that its PD-1 inhibitor Loqtorzi (toripalimab)—when used with bevacizumab—significantly improved survival in patients with advanced hepatocellular carcinoma.